Summit Therapeutics (SMMT) News Today → We’ve Made 1,000% … THREE Different Times in the Last Year (Here’s How) (From Paradigm Press) (Ad) Free SMMT Stock Alerts $7.72 -0.41 (-5.04%) (As of 06/7/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative June 6 at 1:28 AM | americanbankingnews.comSummit Therapeutics (NASDAQ:SMMT) Sees Large Volume Increase Following Analyst UpgradeJune 5 at 3:49 PM | marketbeat.comSummit Therapeutics (NASDAQ:SMMT) Stock Price Up 8.1%Summit Therapeutics (NASDAQ:SMMT) Trading Up 8.1%June 5 at 2:52 AM | americanbankingnews.comSummit Therapeutics (NASDAQ:SMMT) Shares Gap Up Following Analyst UpgradeJune 4, 2024 | marketbeat.comSummit Therapeutics (NASDAQ:SMMT) Sees Strong Trading Volume Following Analyst UpgradeSummit Therapeutics (NASDAQ:SMMT) Sees Unusually-High Trading Volume Following Analyst UpgradeJune 3, 2024 | marketbeat.comSummit Therapeutics (NASDAQ:SMMT) Shares Gap Up After Analyst UpgradeSummit Therapeutics (NASDAQ:SMMT) Shares Gap Up on Analyst UpgradeJune 3, 2024 | americanbankingnews.comSummit Therapeutics (NASDAQ:SMMT) Price Target Raised to $14.00June 3, 2024 | businesswire.comSummit Raises $200 Million; Also Expands License Territories for IvonescimabJune 1, 2024 | businesswire.comIvonescimab Manuscript for HARMONi-A Clinical Trial Results Published in JAMAJune 1, 2024 | americanbankingnews.comSummit Therapeutics (NASDAQ:SMMT) Price Target Increased to $13.00 by Analysts at CitigroupJune 1, 2024 | americanbankingnews.comSummit Therapeutics (NASDAQ:SMMT) Shares Gap Down to $2.94May 31, 2024 | businesswire.comIvonescimab in Combination with Chemotherapy Approved in China by NMPA for 2L+ EGFRm NSCLC based on HARMONi-A Clinical Trial: Positive Trend Observed in Overall Survival towards Ivonescimab Plus ChemotherapyMay 31, 2024 | seekingalpha.comSummit Therapeutics Stock: Plunging Despite A Win?May 30, 2024 | businesswire.comSummit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 30, 2024 | reuters.comSummit Therapeutics cancer therapy succeeds in late-stage China studyMay 30, 2024 | businesswire.comIvonescimab Monotherapy Decisively Beats Pembrolizumab Monotherapy Head-to-Head, Achieves Statistically Significant Superiority in PFS in First-Line Treatment of Patients with PD-L1 Positive NSCLC in ChinaMay 29, 2024 | marketbeat.comSummit Therapeutics (NASDAQ:SMMT) Sees Unusually-High Trading VolumeSummit Therapeutics (NASDAQ:SMMT) Sees Large Volume IncreaseMay 29, 2024 | americanbankingnews.comStock Traders Buy High Volume of Summit Therapeutics Call Options (NASDAQ:SMMT)May 28, 2024 | marketbeat.comSummit Therapeutics (NASDAQ:SMMT) Shares Down 8.9% Summit Therapeutics (NASDAQ:SMMT) Trading Down 8.9%May 28, 2024 | fool.comWhy Summit Therapeutics Stock Is Sinking TodayMay 28, 2024 | marketbeat.comSummit Therapeutics Sees Unusually High Options Volume (NASDAQ:SMMT)Summit Therapeutics Inc. (NASDAQ:SMMT - Get Free Report) saw unusually large options trading activity on Tuesday. Stock traders bought 3,156 call options on the company. This represents an increase of 220% compared to the typical daily volume of 986 call options.May 24, 2024 | finance.yahoo.comSummit Therapeutics Shares Fall After Late-Stage Topline Data for Lung Cancer Treatment AnnouncedMay 22, 2024 | marketbeat.comSummit Therapeutics (NASDAQ:SMMT) Shares Gap Up to $4.39Summit Therapeutics (NASDAQ:SMMT) Shares Gap Up to $4.39May 8, 2024 | seekingalpha.comSummit: A Few Catalysts In Q2 Of 2024 To Carry The TideMay 8, 2024 | marketbeat.comSummit Therapeutics (NASDAQ:SMMT) Sets New 1-Year High at $5.39Summit Therapeutics (NASDAQ:SMMT) Reaches New 52-Week High at $5.39May 7, 2024 | marketbeat.comSummit Therapeutics (NASDAQ:SMMT) Shares Up 8.7%Summit Therapeutics (NASDAQ:SMMT) Stock Price Up 8.7%May 7, 2024 | msn.comSummit spikes as Citi launches at Buy on lead assetMay 7, 2024 | marketbeat.comSummit Therapeutics (NASDAQ:SMMT) Coverage Initiated by Analysts at CitigroupCitigroup assumed coverage on Summit Therapeutics in a research report on Tuesday. They set a "buy" rating and a $7.00 target price on the stock.May 2, 2024 | marketbeat.comSummit Therapeutics (NASDAQ:SMMT) Stock Price Down 6.6%Summit Therapeutics (NASDAQ:SMMT) Stock Price Down 6.6%May 2, 2024 | finance.yahoo.comSummit Therapeutics Inc. (NASDAQ:SMMT) Q1 2024 Earnings Call TranscriptMay 2, 2024 | finance.yahoo.comSummit Therapeutics Inc (SMMT) Q1 2024 Earnings Call Transcript Highlights: Strategic Insights ...May 1, 2024 | investorplace.comSMMT Stock Earnings: Summit Therapeutics Reported Results for Q1 2024May 1, 2024 | finance.yahoo.comSummit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2024April 30, 2024 | marketbeat.comSummit Therapeutics (NASDAQ:SMMT) Trading 3.6% Higher Summit Therapeutics (NASDAQ:SMMT) Trading Up 3.6%April 25, 2024 | marketbeat.comSummit Therapeutics (SMMT) Scheduled to Post Quarterly Earnings on WednesdaySummit Therapeutics (NASDAQ:SMMT) will be releasing earnings before the market opens on Wednesday, May 1, Zacks reports.April 24, 2024 | businesswire.comSummit Therapeutics to Host First Quarter 2024 Financial Results & Operational Progress Call on May 1, 2024April 23, 2024 | marketbeat.comSummit Therapeutics (NASDAQ:SMMT) Shares Up 10.6%Summit Therapeutics (NASDAQ:SMMT) Stock Price Up 10.6%April 13, 2024 | marketbeat.comShort Interest in Summit Therapeutics Inc. (NASDAQ:SMMT) Grows By 28.6%Summit Therapeutics Inc. (NASDAQ:SMMT - Get Free Report) saw a significant growth in short interest in the month of March. As of March 31st, there was short interest totalling 21,810,000 shares, a growth of 28.6% from the March 15th total of 16,960,000 shares. Based on an average daily trading volume, of 2,340,000 shares, the short-interest ratio is presently 9.3 days. Currently, 26.3% of the company's stock are sold short.April 12, 2024 | marketbeat.comSummit Therapeutics (NASDAQ:SMMT) Stock Price Down 6.7%Summit Therapeutics (NASDAQ:SMMT) Trading Down 6.7%April 11, 2024 | finance.yahoo.comSummit Therapeutics Appoints Dr. Mostafa Ronaghi, Renowned Executive and Genomicist, to its Board of DirectorsApril 11, 2024 | businesswire.comSummit Therapeutics Appoints Dr. Mostafa Ronaghi, Renowned Executive and Genomicist, to its Board of DirectorsApril 10, 2024 | businesswire.comSummit Therapeutics to Present at the Stifel 2024 Targeted Oncology ForumApril 9, 2024 | reuters.comIllumina CFO Goswami to depart, Summit Therapeutics' Dhingra named successorApril 9, 2024 | prnewswire.comIllumina appoints Ankur Dhingra Chief Financial Officer, Jakob Wedel Chief Strategy and Corporate Development OfficerApril 4, 2024 | marketbeat.comSummit Therapeutics (NASDAQ:SMMT) Shares Gap Down to $3.95Summit Therapeutics (NASDAQ:SMMT) Shares Gap Down to $3.95April 1, 2024 | marketbeat.comSummit Therapeutics (NASDAQ:SMMT) Stock Price Down 6%Summit Therapeutics (NASDAQ:SMMT) Trading Down 6%March 29, 2024 | investing.comSummit Therapeutics CEO acquires shares worth over $411kMarch 29, 2024 | fool.comWhy Summit Therapeutics Stock Crushed the Market This WeekMarch 29, 2024 | insidertrades.comInsider Buying: Summit Therapeutics Inc. (NASDAQ:SMMT) CEO Acquires 30,000 Shares of StockMarch 28, 2024 | marketbeat.comSummit Therapeutics (NASDAQ:SMMT) Trading 18.9% Higher After Insider Buying ActivitySummit Therapeutics (NASDAQ:SMMT) Trading Up 18.9% Following Insider Buying ActivityMarch 27, 2024 | marketbeat.comInsider Buying: Summit Therapeutics Inc. (NASDAQ:SMMT) CEO Buys 30,000 Shares of StockSummit Therapeutics Inc. (NASDAQ:SMMT - Get Free Report) CEO Mahkam Zanganeh purchased 30,000 shares of the business's stock in a transaction dated Tuesday, March 26th. The shares were purchased at an average cost of $3.75 per share, with a total value of $112,500.00. Following the completion of the purchase, the chief executive officer now directly owns 30,000 shares in the company, valued at $112,500. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Get Summit Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SMMT and its competitors with MarketBeat's FREE daily newsletter. Email Address After Conviction, More Bad News for Trump (Ad)As a former advisor to the CIA, the Pentagon and the White House… I feel it’s my duty to warn you about this coming election meltdown. Click here to see the details because this coming election meltdown could trigger… SMMT Media Mentions By Week SMMT Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. SMMT News Sentiment▼0.570.73▲Average Medical News Sentiment SMMT News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. SMMT Articles This Week▼112▲SMMT Articles Average Week Get Summit Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SMMT and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Jazz Pharmaceuticals News Today Blueprint Medicines News Today Ionis Pharmaceuticals News Today Organon & Co. News Today BridgeBio Pharma News Today Grifols News Today Cytokinetics News Today Apellis Pharmaceuticals News Today Madrigal Pharmaceuticals News Today Alpine Immune Sciences News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:SMMT) was last updated on 6/8/2024 by MarketBeat.com Staff From Our PartnersMillionaire-Making “Wealth Pattern” Just Repeated on April 22If you think you missed out on the Bitcoin band wagon… You need to watch this immediately.Paradigm Press | SponsoredBreaking - The US Gov. Seized CITGODo you want an investment that can double or triple your money in the next three months? The US Court is cu...Augury Research | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredNo Strings Attached: Get 30 Days of Hedgeye’s Top Stock Picks for FreeOptimize your stock investing strategy with Hedgeye's Investing Ideas, where rigorous fundamental stock analys...Hedgeye | SponsoredAI Hell Will Break Loose [June 30, 2024] …On June 30, 2024, AI will reach a critical tipping point… Whatever you do, make sure you prepare before Ju...Banyan Hill Publishing | SponsoredWas the Great Financial Crisis fun?The Great Financial Crisis, which actually started in the summer of 2007 and did not end until March of 2009, ...Brooks Enterprises | SponsoredShocking $16T Elon Musk Crypto LeakReports of a leaked meeting between Elon Musk and staff at X.com could send shockwaves through the crypto mark...Crypto 101 Media | Sponsored